All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Initial results of cilta-cel, a CAR T-cell therapy, in earlier lines of treatment

During the 2021 ASCO Annual Meeting and the EHA2021 Virtual Congress, the Multiple Myeloma Hub spoke with Mounzer Agha, UPMC Hillman Cancer Center, Pittsburgh, US. We asked, What are the initial results of ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor (CAR) T-cell therapy, in earlier lines of treatment?

In this video, Agha presents data from the CARTITUDE-2 trial (NCT04133636) on cilta-cel, a BCMA-directed CAR T-cell therapy, for patients with relapsed/refractory multiple myeloma (RRMM), following 1–3 prior lines of therapy. The primary objective of the study was measurable residual disease (MRD) negativity, while secondary objectives included the overall response rate and duration of response. Agha highlights a manageable safety profile, with the majority of side effects that weren't hematologic being mild, and Grade 3/4 toxicity was uncommon.